Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
SANTA MONICA, Calif., Feb. 24, 2016 -- Kite Pharma, Inc., (Nasdaq:KITE) today announced that it will report fourth quarter and full year 2015 financial results on Monday, February 29, 2016 after market close, and will host a conference call to discuss financial results and provide a business update at 4:30 PM Eastern Time (1:30 PM Pacific Time).
Audio Webcast
Interested parties may access a live audio webcast of the conference call on the Investors section of Kite’s website, www.kitepharma.com. A replay of the webcast will be available on the website for approximately 30 days.
Dial-In Information
Live (U.S. / Canada): (877) 301-8565
Live (International): (678) 562-4240
Confirmation number: 45173015
About Kite Pharma
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous cell therapy (eACT™) designed to restore the immune system's ability to recognize and eradicate tumors. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com. Sign up to follow @KitePharma on Twitter at www.twitter.com/kitepharma.
CONTACT: Greg Mann VP, Investor Relations [email protected] For Media: Justin Jackson Burns McClellan (212) 213-0006 [email protected]
